12,372 trials
Acquired Immunodeficiency Syndrome · HIV Infections
Primary: Percentage of Participants With Onset of Any Treatment-emergent Grade 3 or 4 Adverse Event Between Baseline and Week 24 — 5.4; 11.1 percentage of participants
Alzheimer´s Disease
Primary: Change From Baseline at 18 Months in the Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog) — 7.4; 8.9; 8.4 Scores on a scale — p=0.476
Lung Cancer
Primary: Overall Survival — 6.83; 6.31 Months — p=0.506
Dry Eye Syndromes
Primary: Global Ocular Staining (With Oxford Scale - Ranges :0-15) — -1.8; -2 scores on a scale
Carcinoma
Primary: Overall Survival (OS) — 7.56; 7.33 Months
Mild Cognitive Impairment · Major Depressive Disorder · Alzheimer's Disease
Primary: Change in Selective Reminding Test - Total Immediate Recall (SRT-IR) — 7.5 units on a scale
Breast Cancer
Primary: Progression-Free Survival (PFS) - Percentage of Participants With an Event — 58.6; 58.6 percentage of participants
Amblyopia
Primary: Distribution of 10-week Amblyopic-Eye Visual Acuity — 0; 1; 2; 0 participants
Chronic Kidney Disease · Hyperphosphatemia
Primary: Change in Serum Phosphorus Levels From Week 12 to Week 16 (LOCF) (ITT2) — -0.24; 1.27 mg / dL
Gastric or Duodenal Ulcers Caused by Low-dose Aspirin
Primary: Cumulative Recurrent Rates of Gastric or Duodenal Ulcers — 2.8; 1.4; 21.7 Events/100 participants/24 weeks — p=<0.001
Diabetic Macular Edema
Primary: Mean Change From Baseline in Best Corrected Visual Acuity- (BCVA) at Month 12 — 8.2; 8.9; 0.3 Letters
Type 1 Diabetes Mellitus
Primary: Change From Baseline to Week 24 in HbA1c — -0.21; -0.29; -0.40 Percent of hemoglobin
Idiopathic Thrombocytopenic Purpura
Primary: Percentage of Participants With a Sustained Response — 36; 63 percentage of participants — p=0.004
Fibromyalgia
Primary: Mean NRS Pain Score at End of Period. — 4.84; 5.45 Units on a scale — p=0.0001
Myeloid Leukemia, Chronic, Accelerated Phase · Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Primary: Percent of Participants With Major Hematologic Response (MaHR) With 6 Months of Follow-up From Date of Last Enrollment - Randomized Population — 48.0; 47.9 percentage of…